Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

 
Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them. 

Drugs for  therapy-resitant solid cancers & hypoxic conditions 

 Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors

Colby drugs resore therapy-sensitivity or normoxia
Richard Zare, PhD

Co-Chairman

Richard Zare, PhD is Chairman, Department of Chemistry & Howard Hughes Medical Institute Professor, Stanford University and a Member of the US National Academy of Sciences, Royal Society of Chemistry, Chinese Academy of Sciences, and Swedish Royal Academy.

Dr. Zare is also a Director of the Dreyfus Foundation and is or has been Chair of the President's National Medal of Science, National Research Council Commission, and National Science Board. He has received the National Medal of Science, National Academy of Sciences Award in Chemical Sciences, National Science Board's Distinguished Service Award, Centennial Medal of Harvard University, the Welch Award in Chemistry, and Royal Society of Chemistry Faraday Medal. Dr. Zare has 700-publications and 50-patents. Previously, he was part of the co-founding teams at several companies.